Teva Pharmaceutical Industries vs Viatris
TEVA and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TEVA and VTRS compare
Teva Pharmaceutical Industries is the larger company, worth 2.2 times as much as Viatris ($48.3B against $21.9B).
Viatris grew revenue faster over the last twelve months (4.4% versus −15.2% for Teva Pharmaceutical Industries).
Viatris pays a dividend yielding 2.5%; Teva Pharmaceutical Industries does not pay one.
Teva Pharmaceutical Industries scores higher on the StockData Score (7 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TEVA | VTRS |
|---|---|---|
| Size and price | ||
| Market cap | $48.3B | $21.9B |
| Share price | $41.47 | $19.04 |
| Change, 1 year | 110% | 85.3% |
| Change, 5 years | 354% | 38.6% |
| Beta (5Y) | 0.99 | 0.87 |
| Employees | 34K | 30K |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 69.1× | – |
| P/S | 3.4× | 1.5× (better) |
| P/B | 6.2× | – |
| EV/EBITDA | 19.0× | 12.6× (better) |
| P/FCF | 35.8× | 11.2× (better) |
| FCF yield | 2.8% | 8.9% (better) |
| Fair value | $18.65 | $20.87 |
| Margin of safety | −122% | 8.8% (better) |
| Growth | ||
| Revenue growth (TTM) | −15.2% | 4.4% (better) |
| Revenue growth, 5Y average | 0.71% | 3.7% (better) |
| Profitability | ||
| Gross margin | 64.4% (better) | 34.8% |
| Operating margin | 11.4% (better) | −0.59% |
| Net margin | 5.0% | – |
| FCF margin | 9.6% | 13.3% (better) |
| Return on equity | 9.7% | – |
| Return on invested capital | 23.0% | – |
| Financial health | ||
| Debt / equity | 0.58 | – |
| Net debt / EBITDA | 0.33 (better) | 4.59 |
| Interest coverage | – | −0.2× |
| Current ratio | 0.88 | 1.58 (better) |
| Altman Z-score | 0.84 | 1.16 (better) |
| Piotroski F-score | 8 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 2.5% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | 1.4% |
| Shareholder yield | 0.00% | 3.9% (better) |
| Ownership | ||
| Held by institutions | – | 91.5% |
| Held by insiders | 0.43% | 0.36% |
| Insider net buying, 12 months | −$113M | −$1.1M (better) |
| Superinvestors holding | – | 3 |
| Short interest, % of float | 2.6% | 3.7% |
Go deeper
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
- VTRS stock overview
- VTRS income statement
- VTRS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.